Chengda Biotech announced that the 33rd meeting of the fifth board of directors of the company deliberated and passed a number of proposals: first, it is proposed to adjust some of the fund-raising project sub-projects, and continue to store the remaining funds raised for special account management; second, it is proposed to use 25 million yuan to 50 million yuan of overraised capital to repurchase A-shares through centralized bidding at a price of no more than 30.00 yuan/share. The repurchase shares will all be used to cancel and reduce registered capital; third, it is planned to hold the 2026 3rd Extraordinary Shareholders' Meeting on November 27, 2026 to consider the matters requiring consideration by the shareholders' meeting.

Chengda Biotech announced that the 33rd meeting of the fifth board of directors of the company deliberated and passed a number of proposals: first, it is proposed to adjust some of the fund-raising project sub-projects, and continue to store the remaining funds raised for special account management; second, it is proposed to use 25 million yuan to 50 million yuan of overraised capital to repurchase A-shares through centralized bidding at a price of no more than 30.00 yuan/share. The repurchase shares will all be used to cancel and reduce registered capital; third, it is planned to hold the 2026 3rd Extraordinary Shareholders' Meeting on November 27, 2026 to consider the matters requiring consideration by the shareholders' meeting.